TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

BEIJING

OncologyImmunologyInfectious Disease
Generics

BEIJING is a generic drug manufacturer focused on Oncology, Immunology, Infectious Disease.

2021
Since
2
Drugs
-
Trials
5
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

NIACIN 2025-07-25
NIACIN 2025-04-28
NIACIN 2025-04-10
Labeling
FLUVASTATIN SODIUM 2024-09-24
Labeling
FLUVASTATIN SODIUM 2024-07-11
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 50%
0 drugs Phase 3: 11 Phase 2: 21 Phase 1: 51
Immunology 14%
0 drugs Phase 3: 3 Phase 2: 7 Phase 1: 13
Infectious Disease 14%
0 drugs Phase 3: 6 Phase 2: 5 Phase 1: 5
Metabolic 11%
0 drugs Phase 3: 3 Phase 2: 4 Phase 1: 10
Gastroenterology 11%
0 drugs Phase 3: 4 Phase 2: 5 Phase 1: 3

Pipeline Strength Pro

Loading...

Competitors Pro

Pfizer big-pharma
Oncology, Infectious Disease, Immunology, Gastroenterology
Merck big-pharma
Oncology, Infectious Disease, Immunology, Metabolic
Johnson & Johnson big-pharma
Oncology, Immunology, Infectious Disease, Metabolic
Sanofi big-pharma
Metabolic, Oncology, Infectious Disease, Immunology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology, Infectious Disease